Subscribe to the Daily PV Brief for breaking drug safety news, regulatory updates, and pharmacovigilance insights.
Daily News and Intelligence for the Pharmacovigilance Industry
Stay informed with timely coverage of drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, compliance trends, and career insights from across the global PV landscape.
CVMP March 2026 Highlights Keep Veterinary Safety in View
EMA’s March 2026 veterinary committee highlights are a useful reminder that regulatory safety visibility is active in animal health too.
Today in PV
A quick scan of the latest stories, safety concerns, regulatory developments, and industry signals every pharmacovigilance professional should know today.
Explore Coverage
Browse the key areas shaping pharmacovigilance today, from global regulatory updates to safety signals, compliance trends, AI, and career growth.
Regulatory Updates
Track key developments from FDA, EMA, MHRA, WHO, NAFDAC, Health Canada, TGA, SAHPRA, and other health authorities.
Inspections & Compliance
Stay current on inspection readiness, CAPAs, SOP expectations, audit trends, and the compliance issues shaping PV systems.
Explainers
Clear, practical breakdowns of PV concepts, industry terms, reporting frameworks, and regulatory changes.
Careers
Insights for professionals building or advancing careers in pharmacovigilance, drug safety, compliance, and related functions.
Safety Signals
Follow emerging risks, label changes, recalls, medication errors, and other safety issues that matter in real-world pharmacovigilance.
AI & Digital PV
Explore how artificial intelligence, automation, and digital tools are influencing case processing, signal detection, and safety operations.
Latest News
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam. Aque ipsa quae ab illo inventore veritatis. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accus antium doloremque.
MHRA Approves Deuruxolitinib for Severe Alopecia Areata
MHRA has approved deuruxolitinib for adults with severe alopecia areata, while making clear that safety and effectiveness will remain under review.
MHRA and NICE Launch Faster Joint Approval Pathway
MHRA and NICE say their new aligned pathway could bring some medicines to patients in England three to six months earlier.
FDA Requests Removal of Suicidal Ideation Warning From Certain GLP-1 Labels
FDA says its review did not identify an increased risk of suicidal ideation or behavior with certain GLP-1 receptor agonists and is requesting label updates.
FDA Requires Vitamin B6 Deficiency Warning for Carbidopa/Levodopa
FDA is requiring updated labeling for carbidopa/levodopa products to warn about vitamin B6 deficiency and related seizures, adding a new monitoring point for Parkinson’s treatment.
Why MHRA’s Weekly Field Safety Notices Still Matter for Safety Monitoring
MHRA’s weekly Field Safety Notices may look routine, but they remain an important visibility tool for device-related safety communication.
Ramipril Recall After Packaging Error Raises Medication Mix-Up Risk
A precautionary recall of Ramipril 5 mg Capsules in the UK highlights how packaging errors can quickly become patient-safety events.
Featured Posts
Global Watch Weekly: MHRA, EMA Shortages and Veterinary Developments
This week’s global watch includes an MHRA approval with explicit safety follow-up, fresh ESMP activity at EMA, and continued visibility for veterinary regulation.
Week in PV: FDA B6 Warning, GLP-1 Label Change and PRAC Updates
This week’s PV highlights include a new FDA warning for carbidopa/levodopa products, a GLP-1 label reversal, and fresh PRAC visibility from Europe.
Why Real-Time Safety Visibility Is Becoming a Regulatory Strategy
Between AEMS, public dashboards, and standing safety communication pages, regulators are building a more visible safety-information environment.
Why MHRA’s 30-Day Type II Safety Variation Route Matters
MHRA’s reduced 30-day Type II route for safety issues shows that some pharmacovigilance-driven changes require a faster regulatory response than standard variation timelines.
Why MHRA’s 30-Day Type II Safety Variation Route Matters
MHRA’s reduced 30-day Type II procedure for safety issues is a useful signal that some pharmacovigilance-driven changes need faster regulatory handling than standard variation timelines allow.
A Missing Safety Warning in a PIL Became a Bigger GPvP Lesson
MHRA’s amitriptyline defect notification is a useful reminder that GPvP findings can show up in patient-facing materials, not just safety databases and SOPs.
A Missing PIL Warning, a GPvP Inspection, and a Bigger Compliance Lesson
An MHRA defect notification linked missing leaflet safety information to a GPvP inspection, offering a useful reminder that pharmacovigilance findings can surface in product-facing materials.
Why EudraVigilance Training Is a Compliance Requirement in Practice
MA’s EudraVigilance framework makes a clear point: in regulated safety systems, training is not just onboarding. It is part of operational control.
What the Amended CIR 520/2012 Means for Some UK-Authorised Products
The UK has its own regulatory system, but the February 2026 amendments to EU CIR 520/2012 still carry practical implications for some UK-authorised medicines.
Contact us
Email Us
editor@pvwatchdaily.com